Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: Comparison of clinical results obtained with BNCT and conventional treatment

Kageji, Teruyoshi; Saijo, Nagahiro; Mizobuchi, Yoshifumi; Matsuzaki, Kei; Nakagawa, Yoshinobu; Kumada, Hiroaki

doi:10.2152/jmi.61.254

Cited by 35 publications

(28 citation statements)

References 29 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After that, the patient is irradiated with epithermal neutrons until the normal tissue dose limit is reached. When the nonradioactive boron atom captures the thermalized neutron, there will be a decaying process where the thermalized neutron decays through short-range -particle and recoiling Li-7 nucleus (Kageji et al 2014). These emitted charged particles can travel only a short distance (10 µm), have a high linear energy transfer, and have an associated high relative biological effectiveness (Wang et al 2018).…”

Section: Resultsmentioning

confidence: 99%

Overview of Boron Neutron Capture Therapy: a Medical Aspect

Bangun

Poedjomartono

2018

AJSTD

View full text Add to dashboard Cite

Cancer is an abnormal growth of a cell due to the cell’s inability to control and maintain its proliferation, differentiation and apoptosis cycle. There are several methods to treat cancer; one of which is boron neutron capture therapy (BNCT). BNCT is a radiation modality by which a high radiation dose is delivered to tumor cells with lower damage to surrounding normal tissue. This modality has been used widely as a treatment for several cancer cases, such as head and neck cancer, breast cancer, and liver cancer. BNCT uses sodium borocaptate (BSH) or boronophenylalanine (BPA) as the delivery agent. Then, the tumor cell is irradiated by thermal radiation. This technique has excellent potential to become a main method of cancer therapy in the future, since it is noninvasive and has fewer side effects than other methods. Further studies on BNCT are needed to improve its performance as a cancer treatment modality.

show abstract

Section: Resultsmentioning

confidence: 99%

Overview of Boron Neutron Capture Therapy: a Medical Aspect

Bangun

Poedjomartono

2018

AJSTD

View full text Add to dashboard Cite

show abstract

“…In this study, we further verify the welfares of honokiol to efficiently kill human TMZ-resistant glioblastoma cells. Human malignant glioblastomas are very aggressive and recurrent [2]. Most of glioblastoma patients are drug-resistant and recurrent [3,4].…”

Section: Discussionmentioning

confidence: 99%

“…Glioblastomas are the most common and aggressive brain tumors [1]. The patients with malignant glioblastomas usually have poor prognosis [2]. The median survival rate of glioblastoma patients is about 12 months.…”

Section: Introductionmentioning

confidence: 99%

Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells

Yang

Chen

2020

Molecules

View full text Add to dashboard Cite

Temozolomide (TMZ)-induced chemoresistance to human glioblastomas is a critical challenge now. Our previous studies showed that honokiol, a major bioactive constituent of Magnolia officinalis (Houpo), can kill human glioblastoma cells and suppresses glioblastoma growth. This study was further aimed to evaluate the effects of honokiol on human drug-resistant glioblastoma cells and the possible mechanisms. The results by data mining in the cancer genome atlas (TCGA) database and immunohistochemistry displayed that expression of caspase-9 mRNA and protein in human glioblastomas was induced. Human TMZ-resistant U87-MG-R9 glioblastoma cells were selected and prepared from human drug-sensitive U87-MG cells. Compared to human drug-sensitive U87-MG cells, TMZ did not affect viability of U87-MG-R9 glioblastoma cells. Interestingly, treatment with honokiol suppressed proliferation and survival of human drug-resistant glioblastoma cells in concentration- and time-dependent manners. Compared to caspase-8 activation, honokiol chiefly increased activity of caspase-9 in U87-MG-R9 cells. Successively, levels of cleaved caspase-3 and activities of caspase-3 and caspase-6 in human TMZ-tolerant glioblastoma cells were augmented following honokiol administration. In parallel, honokiol triggered DNA fragmentation of U87-MG-R9 cells. Accordingly, treatment of human TMZ-resistant glioblastoma cells with honokiol induced cell apoptosis but did not affect cell necrosis. Fascinatingly, suppressing caspase-9 activity using its specific inhibitors repressed honokiol-induced caspase-6 activation, DNA fragmentation, and cell apoptosis. Taken together, this study has shown the major roles of caspase-9 in transducing honokiol-induced mitochondria-dependent apoptosis in human drug-resistant glioblastoma cells. Thus, honokiol may be clinically applied as a drug candidate for treatment of glioblastoma patients with chemoresistance.

show abstract

“…Malignant melanoma requires extensive resection. These tumors were chosen as the initial targets of BNCT that can selectively destroy the tumor by high‐LET particles with a short path length . The penetration of tissue by thermal neutrons is 3‐4 cm.…”

Section: Boron Neutron Capture Therapymentioning

confidence: 99%

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Yura

Tada

Fujita

et al. 2019

Oral Science International

View full text Add to dashboard Cite

Malignant tumors such as squamous cell carcinoma (SCC), malignant salivary gland tumor, mucosal melanoma, sarcoma, and lymphoma occur in the oral cavity. Among them, oral SCC accounts for 90%. The frequency of lymph node metastasis of oral SCC varies depending on the site of occurrence, which affects the prognosis. Surgery is the primary treatment for oral cancer, but when the tumor extends, postoperative radiation with or without chemotherapy is required. Photons including X-rays and γ-rays are the most widely used types of ionizing radiation in cancer radiotherapy. Particle radiotherapy using protons and carbon ions shows a highly focused dose distribution to tumor tissues. Carbon ion therapy is effective for salivary gland tumors, malignant melanomas, and sarcomas which are less susceptible to photons. Furthermore, boron neutron capture therapy with tumor selectivity is expected to further reduce damage to surrounding normal cells. The introduction of novel radiotherapy to current treatment might improve the prognosis of patients and organ preservation. K E Y W O R D S chemotherapy, oral cancer, particle radiotherapy, radiotherapy, surgery How to cite this article: Yura Y, Tada S, Fujita Y, Hamada M. Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. Oral Sci Int. 2019;16:49-68. https://doi.

show abstract

Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: Comparison of clinical results obtained with BNCT and conventional treatment

Cited by 35 publications

References 29 publications

Overview of Boron Neutron Capture Therapy: a Medical Aspect

Overview of Boron Neutron Capture Therapy: a Medical Aspect

Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Contact Info

Product

Resources

About